DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
TRIBE-2: a phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
BMC Cancer (2017) 17:408 DOI 10.1186/s12885-017-3360-z
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
British Journal of Cancer (2017), 1–6 | doi: 10.1038/bjc.2016.413
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
European Journal of Cancer xx (2016) 1e11
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
Ann Oncol. 2015 Apr;26(4):724-30. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Ann Oncol. 2015 Jun;26(6):1188-94. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014.
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Eur J Cancer. 2014 Jan;50(1):57-63. doi: 10.1016/j.ejca.2013.08.024. Epub 2013 Oct 15.
